Patent Application Highlights AlbuVoid™ in Cell-based Drug Toxicity Assays
Biotech Support Group reports on a new patent application which highlights the simplicity of their albumin depletion sample preparation technology as an enrichment step for serum containing medium used in cell culture for LC-MS proteomic analysis

News Release


Patent Application Highlights AlbuVoid™ in Cell-based Drug Toxicity Assays


MONMOUTH JUNCTION, NJ, October 15, 2019 -- Biotech Support Group reports on a new patent application which highlights the simplicity and efficiency of their Albumin depletion sample preparation technology as an enrichment step for serum containing medium used in cell culture for LC-MS proteomic analysis. The citation is:


Narain, Niven Rajin, Rangaprasad Sarangarajan, and Vivek K. Vishnudas. "Interrogatory cell-based assays for identifying drug-induced toxicity markers." U.S. Patent Application No. 16/180,446.


The lack of reliable tools that can help with predicting toxicity early in drug development is partly to blame for a 90% attrition of potential compounds entering clinical development, 30% of which is owing to poor clinical safety. Cardiotoxicity particularly is a leading cause of drug withdrawal. The invention described is useful for identifying markers associated with drug-induced toxicity. The patent application states “In one embodiment, the cells can be cultured in serum containing medium: The volume of the medium can be reduced using 3 k MWCO Vivaspin columns (GE Healthcare Life Sciences), then can be reconstituted with 1×PBS (Invitrogen). Serum albumin can be depleted from all samples using AlbuVoid column (Biotech Support Group, LLC) following the manufacturer's instructions with the modifications of buffer-exchange to optimize for condition medium application.” The patent description includes a novel, collaborative utilization of network biology, genomic, proteomic, metabolomic, transcriptomic, and bioinformatics tools and methodologies, which, when combined, may be used to study any biological system of interest, such as obtaining insight into the molecular mechanisms associated with or causal for drug-induced toxicity.


I are very pleased to see that AlbuVoid™ was referenced for the proteomic analysis of cell culture. As we do not use immunoaffinity, separations are efficient across all species” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.


For more information on AlbuVoid™, go to: http://www.biotechsupportgroup.com/AlbuVoid-Albumin-Depletion-and-Low-Abundance-p/avk.htm


For more information on the BSG complete line of Albumin & IgG Removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=451


About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

Contact:
Matthew Kuruc 732-274-2866,
mkuruc@biotechsupportgroup.com